Keyphrases
Atomoxetine
100%
Stimulant Treatment
100%
Suicidal Event
100%
Stimulants
33%
First Year
22%
Suicidal Ideation
22%
Suicide Risk
22%
Suicide Attempt
22%
Pediatric Patients
22%
Adjusted Hazard Ratio
22%
Second-line Treatment
22%
Stimulant Use
22%
Clinical Trials
11%
Antidepressants
11%
High-risk Population
11%
Depression Treatment
11%
Suicide
11%
Suicidality
11%
Risk Assessment
11%
Confidence Interval
11%
Cox Proportional Hazards Model
11%
Public Concern
11%
Youth Age
11%
Medicaid Program
11%
Clinical Trial Data
11%
Low Incidence
11%
Stratified Analysis
11%
Propensity Score
11%
Initiating Treatment
11%
Attention-deficit-hyperactivity-disorder, Treatment
11%
Retrospective Cohort Design
11%
Serotonin-noradrenaline Reuptake Inhibitor
11%
Medicine and Dentistry
Cohort Analysis
100%
Analeptic
100%
Atomoxetine
100%
Clinical Trial
22%
Hazard Ratio
22%
Pediatrics Patient
22%
Combination Therapy
11%
High Risk Population
11%
Proportional Hazards Model
11%
Attention Deficit Disorder
11%
Medicaid
11%
Treatment of Depression
11%
Post-Hoc Analysis
11%
Norepinephrine Reuptake Inhibitor
11%
Antidepressant Activity
11%
Adolescence
11%
Nursing and Health Professions
Cohort Analysis
100%
Atomoxetine
100%
Central Stimulant Agent
100%
Hazard Ratio
22%
Pediatrics Patient
22%
High Risk Population
11%
Combination Therapy
11%
Adolescent
11%
Attention Deficit Disorder
11%
Confidence Interval
11%
Medicaid
11%
Proportional Hazards Model
11%
Propensity Score
11%
Post Hoc Analysis
11%
Norepinephrine Reuptake Inhibitor
11%
Antidepressant
11%
Psychology
Hazard Ratio
100%
Medicaid
50%
Attention Deficit Hyperactivity Disorder
50%
High-Risk Population
50%
Proportional Hazards Regression Model
50%
Adolescence
50%
Norepinephrine
50%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Atomoxetine
100%
Clinical Trial
22%
Antidepressant
11%
Combination Therapy
11%
Attention Deficit Disorder
11%
Norepinephrine Reuptake Inhibitor
11%
Neuroscience
Analeptic
100%
Atomoxetine
100%
Antidepressant
11%
Attention Deficit Hyperactivity Disorder
11%
Treatment of Depression
11%
Norepinephrine Reuptake Inhibitor
11%